Celltrion nabs EU approval of first subcutaneous infliximab biosimilar

26 November 2019

South Korea’s Celltrion Healthcare (Kosdaq: 068270) today announced that the European Commission has approved Remsima SC (CT-P13 SC, biosimilar infliximab) for patients with rheumatoid arthritis (RA).

Remsima SC is the world’s first subcutaneous formulation of infliximab, which is marketed as Remicade by Johnson & Johnson (NYSE: JNJ) subsidiary Janssen. Remsima SC will launch in major markets such as Germany, the UK and the Netherlands in the first quarter of 2020, estimated to be worth $4 billion. By the fourth quarter, the domination rate is expected to reach 89%, worth $7.9 billion, according to Celltrion’s projections.

Celltrion was the first drug developer to win approval for a biosimilar monoclonal antibody (MAb) from the European Medicines Agency (EMA) in 2013 and the US Food and Drug Administration (FDA) with its copy of Remicade in 2016, although several others have since been approved.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK